JOURNAL OF UROLOGY Journal
Overview
publication venue for
- Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. 215. 2026
- Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. 215:396-407. 2026
- ISOPSA LARGE SCALE PROSPECTIVE VALIDATION STUDY: PERFORMANCE OF THE ISOPSA TEST IN PATIENTS AGED 50-69 YEARS 2025
- IP21-27 IsoPSA LARGE SCALE PROSPECTIVE VALIDATION STUDY: PERFORMANCE OF THE IsoPSA TEST IN PATIENTS AGED 50-69 YEARS. 213. 2025
- Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. 212:74-86. 2024
- EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUERIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL 2024
- PIVOTAL STUDY EVALUATING PERFORMANCE OF BLADDER EPICHECK, AN FDA CLEARED TEST, IN NON-MUSCLE INVASIVE BLADDER CANCER 2024
- Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. 211:415-425. 2024
- Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma. 211:90-100. 2024
- Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. 211:415-425. 2024
- Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. 212:74-86. 2024
- TREATMENT PATTERN AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN THE UNITED STATES (US) 2023
- Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. 207:61-68. 2022
- Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. 207:61-69. 2022
- Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. 207:61-69. 2022
- A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy. 206:942-951. 2021
- ANTI-ADENOVIRAL ANTIBODY LEVELS PREDICT NADOFARAGENE FIRADENOVEC RESPONSE IN BCG-UNRESPONSIVE NMIBC: RESULTS FROM A PHASE 3 TRIAL 2021
- IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER 2021
- PRIMARY CHEMOABLATION OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER USING UGN-102, A MITOMYCIN-CONTAINING REVERSE THERMAL GEL (OPTIMA II): A PHASE 2B, OPEN-LABEL, SINGLE-ARM TRIAL 2021
- RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN 2021
- A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III) 2019
- CHARACTERIZATION OF LONG-TERM SURVIVORS FROM PROCEED, A REGISTRY OF SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 2019
- MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY 2019
- DECIPHER TEST IMPACTS ADJUVANT AND SALVAGE TREATMENTS RECEIVED FOLLOWING RADICAL PROSTATECTOMY. 2018
- SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES 2018
- A 17-GENE PANEL FOR PREDICTION OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY: PROSPECTIVE VALIDATION 2017
- A PHASE III BLINDED STUDY OF IMMEDIATE POST-TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON-MUSCLE INVASIVE BLADDER CANCER: SWOG S0337 2017
- DECIPHER TEST IMPACTS DECISION-MAKING AMONG PATIENTS CONSIDERING ADJUVANT AND SALVAGE TREATMENT FOLLOWING RADICAL PROSTATECTOMY: INTERIM RESULTS FROM THE MULTICENTER PROSPECTIVE PRO-IMPACT STUDY 2017
- MP28-01 A 17-GENE PANEL FOR PREDICTION OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY: PROSPECTIVE VALIDATION. 197. 2017
- PD71-01 DECIPHER TEST IMPACTS DECISION-MAKING AMONG PATIENTS CONSIDERING ADJUVANT AND SALVAGE TREATMENT FOLLOWING RADICAL PROSTATECTOMY: INTERIM RESULTS FROM THE MULTICENTER PROSPECTIVE PRO-IMPACT STUDY. 197. 2017
- PNFLBA-10 A PHASE III BLINDED STUDY OF IMMEDIATE POST-TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON-MUSCLE INVASIVE BLADDER CANCER: SWOG S0337. 197. 2017
- A PHASE 2 STUDY OF VESIMUNE®, INTRAVESICAL IMIQUIMOD, FOR THE TREATMENT OF CARCINOMA IN SITU BLADDER CANCER 2016
- IMPROVED EFFICACY OF ADJUVANT, SINGLE DOSE INTRAVESICAL APAZIQUONE BY TIMING POST-RESECTION IN TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES IN NON-MUSCLE INVASIVE BLADDER CANCER 2016
- INTEGRATED RESULTS OF TWO MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, PHASE 3 TRIALS (SPI-611/612) OF SINGLE-DOSE INTRAVESICAL APAZIQUONE IMMEDIATELY FOLLOWING RESECTION IN PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER 2016
- RENAL FUNCTION BEFORE AND AFTER CYTOREDUCTIVE NEPHRECTOMY IN A PHASE 3 RANDOMIZED CLINICAL TRIAL 2016
- LB-S&T-21 A PHASE 2 STUDY OF VESIMUNE®, INTRAVESICAL IMIQUIMOD, FOR THE TREATMENT OF CARCINOMA IN SITU BLADDER CANCER. 195. 2016
- MP13-07 IMPROVED EFFICACY OF ADJUVANT, SINGLE DOSE INTRAVESICAL APAZIQUONE BY TIMING POST-RESECTION IN TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES IN NON-MUSCLE INVASIVE BLADDER CANCER. 195. 2016
- PD04-02 RENAL FUNCTION BEFORE AND AFTER CYTOREDUCTIVE NEPHRECTOMY IN A PHASE 3 RANDOMIZED CLINICAL TRIAL. 195. 2016
- PD11-07 INTEGRATED RESULTS OF TWO MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, PHASE 3 TRIALS (SPI-611/612) OF SINGLE-DOSE INTRAVESICAL APAZIQUONE IMMEDIATELY FOLLOWING RESECTION IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER. 195. 2016
- RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T AND ANDROGEN DEPRIVATION THERAPY (STAND) IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: PRELIMINARY CLINICAL OUTCOMES 2015
- TERRAIN TRIAL: PROSTATE-SPECIFIC ANTIGEN KINETICS AND QUALITY OF LIFE RESULTS OF ENZALUTAMIDE VERSUS BICALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER 2015
- MP87-15 RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T AND ANDROGEN DEPRIVATION THERAPY (STAND) IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: PRELIMINARY CLINICAL OUTCOMES. 193. 2015
- TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED 2014
- MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED. 191. 2014
- CLINICAL EVALUATION OF TREATMENT OF PEYRONIE'S DISEASE WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: ANALYSIS OF PENILE CURVATURE DEFORMITY BY DURATION OF DISEASE AND PLAQUE CALCIFICATION 2013
- TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED 2013
- 1656 CLINICAL EVALUATION OF TREATMENT OF PEYRONIE'S DISEASE WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: ANALYSIS OF PENILE CURVATURE DEFORMITY BY DURATION OF DISEASE AND PLAQUE CALCIFICATION. 189. 2013
- 972 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED. 189. 2013
- Systemic Buffers Inhibit Carcinogenesis in TRAMP Mice. 188:624-631. 2012
- Factors Affecting Return of Continence 3 Months After Robot-Assisted Radical Prostatectomy: Analysis From a Large, Prospective Data by a Single Surgeon. 187:190-194. 2012
- Positive Surgical Margins After Robotic Assisted Radical Prostatectomy: A Multi-Institutional Study. 186:511-516. 2011
- Training, Credentialing, Proctoring and Medicolegal Risks of Robotic Urological Surgery: Recommendations of the Society of Urologic Robotic Surgeons. 182:1126-1132. 2009
- Optimal Parameters for the Destruction of Prostate Cancer Using Irreversible Electroporation. 180:2668-2674. 2008
- Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. 179:81-86. 2008
- Robotic radical prostatectomy in the community setting - The learning curve and beyond: Initial 200 cases. 174:269-272. 2005
- Estimation of acute blood loss in the anticoagulated rabbit model using 3 modalities of radio frequency energy ablation. 170:970-974. 2003
- PRIMARY RENAL LYMPHOMA. 146:1588-1590. 1991
- STAGE-II NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - AN ANALYSIS OF TREATMENT OPTIONS IN PATIENTS WITH LOW VOLUME RETROPERITONEAL DISEASE. 140:1437-1441. 1988
- CELL-SPECIFIC RIBOSOMAL DNA SPACER VARIABILITY IN HUMAN UROTHELIAL CARCINOMA CULTURES. 137:324-326. 1987
Research
category
- UROLOGY & NEPHROLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0022-5347
Electronic International Standard Serial Number (EISSN)
- 1527-3792
Other
journal abbreviation
- J UROLOGY